BerisÅ‚av V ZlokoviÄ

List of Publications by Year
in descending order

274	51,102	2203	1561
papers	citations	99 h-index	217 g-index

290	290	290	37103
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The small HDL particle hypothesis of Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 391-404.	0.4	18
2	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. Journal of Experimental Medicine, 2022, 219, .	4.2	12
3	A single-cell atlas of the normal and malformed human brain vasculature. Science, 2022, 375, eabi7377.	6.0	129
4	Brain barriers and their potential role in migraine pathophysiology. Journal of Headache and Pain, 2022, 23, 16.	2.5	17
5	Bloodâ€“brain barrier link to human cognitive impairment and Alzheimerâ€™s disease. , 2022, 1, 108-115.		45
6	3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice. Frontiers in Neuroscience, 2022, 16, 841916.	1.4	8
7	Prenatal disruption of bloodâ€“brain barrier formation via cyclooxygenase activation leads to lifelong brain inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113310119.	3.3	15
8	Imaging subtle leaks in the bloodâ€“brain barrier in the aging human brain: potential pitfalls, challenges, and possible solutions. GeroScience, 2022, 44, 1339-1351.	2.1	17
9	How the brain regulates its own immune system. Nature Neuroscience, 2022, 25, 532-534.	7.1	7
10	Characterization of perivascular space pathology in a rat model of cerebral small vessel disease by in vivo magnetic resonance imaging. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1813-1826.	2.4	8
11	A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. Translational Stroke Research, 2021, 12, 15-30.	2.3	18
12	Cranial Suture Regeneration Mitigates Skull and Neurocognitive Defects in Craniosynostosis. Cell, 2021, 184, 243-256.e18.	13.5	88
13	Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. Journal of Experimental Medicine, 2021, 218, .	4.2	59
14	Evidence that bloodâ€“CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen. Headache, 2021, 61, 536-545.	1.8	13
15	Investigating the bloodâ€“spinal cord barrier in preclinical models: a systematic review of in vivo imaging techniques. Spinal Cord, 2021, 59, 596-612.	0.9	5
16	Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. Frontiers in Neurology, 2021, 12, 593582.	1.1	11
17	On the intersection between systemic infection, brain vascular dysfunction and dementia. Brain, 2021, 144, 1629-1631.	3.7	0
18	Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. Brain, Behavior, and Immunity, 2021, 94, 299-307.	2.0	19

#	Article	IF	Citations
19	APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimerâ€™s mice via cyclophilin A independently of amyloid-Î². Nature Aging, 2021, 1, 506-520.	5.3	77
20	Acetylated tau: A missing link between head injury and dementia. Med, 2021, 2, 637-639.	2.2	1
21	Reply to: Rethink the classical view of cerebrospinal fluid production. Nature Reviews Neurology, 2021, 17, 590-591.	4.9	1
22	Editorial for â€œ<scp>MRIâ€Based</scp> Investigation of Association Between Cerebrovascular Structural Alteration and White Matter Hyperintensity Induced by High Blood Pressureâ€• Journal of Magnetic Resonance Imaging, 2021, 54, 1527-1528.	1.9	0
23	Air Pollution Particulate Matter Exposure and Chronic Cerebral Hypoperfusion and Measures of White Matter Injury in a Murine Model. Environmental Health Perspectives, 2021, 129, 87006.	2.8	22
24	Microglia have a grip on brain microvasculature. Nature Communications, 2021, 12, 5290.	5.8	20
25	Air Pollution Particulate Matter Amplifies White Matter Vascular Pathology and Demyelination Caused by Hypoperfusion. Frontiers in Immunology, 2021, 12, 785519.	2.2	14
26	The relationship between bloodâ€brain barrier permeability and cerebral blood flow in cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0
27	Urine dicarboxylic acids are metabolic biomarkers of early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
28	Can prehospital â€œplasma supplementâ€•neutralize the systemic storm in severe trauma?. Cell Reports Medicine, 2021, 2, 100481.	3.3	1
29	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-Î± in APOE4 carriers. Neurobiology of Aging, 2020, 86, 112-122.	1.5	22
30	Every-other-day feeding exacerbates inflammation and neuronal deficits in 5XFAD mouse model of Alzheimer's disease. Neurobiology of Disease, 2020, 136, 104745.	2.1	21
31	Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimer's and Dementia, 2020, 16, 1714-1733.	0.4	108
32	Endothelial Tip Cell Finds Its Way with Piezo1. Neuron, 2020, 108, 5-7.	3.8	3
33	Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid. Journal of Neuroscience, 2020, 40, 8573-8586.	1.7	60
34	Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. EBioMedicine, 2020, 59, 102883.	2.7	70
35	Clearance of interstitial fluid (ISF) and CSF (CLIC) groupâ€”part of Vascular Professional Interest Area (PIA). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12053.	1.2	53
36	Therapeutic TVs for Crossing Barriers in the Brain. Cell, 2020, 182, 267-269.	13.5	13

#	Article	IF	Citations
37	Comparison Between Blood-Brain Barrier Water Exchange Rate and Permeability to Gadolinium-Based Contrast Agent in an Elderly Cohort. Frontiers in Neuroscience, 2020, 14, 571480.	1.4	30
38	Microglial activation: A process potentially related to Alzheimer's disease and lateâ€life major depression. Alzheimer's and Dementia, 2020, 16, e041950.	0.4	0
39	Relationships between cerebrovascular health and tau PET uptake are associated with global cognition. Alzheimer's and Dementia, 2020, 16, e045326.	0.4	0
40	Channelrhodopsin Excitation Contracts Brain Pericytes and Reduces Blood Flow in the Aging Mouse Brain in vivo. Frontiers in Aging Neuroscience, 2020, 12, 108.	1.7	56
41	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. PLoS ONE, 2020, 15, e0232785.	1.1	31
42	Acute Ablation of Cortical Pericytes Leads to Rapid Neurovascular Uncoupling. Frontiers in Cellular Neuroscience, 2020, 14, 27.	1.8	50
43	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. Stroke, 2020, 51, 2236-2239.	1.0	1
44	APOE4 Accelerates Development of Dementia After Stroke. Stroke, 2020, 51, 699-700.	1.0	16
45	Perivascular spaces in the brain: anatomy, physiology and pathology. Nature Reviews Neurology, 2020, 16, 137-153.	4.9	405
46	APOE4 leads to bloodâ€“brain barrier dysfunction predicting cognitive decline. Nature, 2020, 581, 71-76.	13.7	705
47	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, 821-830.	0.4	43
48	Building vascular roadmaps: A novel toolset for visualizing and annotating whole mouse brain vasculature. Lab Animal, 2020, 49, 175-176.	0.2	1
49	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
50	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
51	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
52	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
53	Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimer's and Dementia, 2019, 15, 961-984.	0.4	200
54	Mitigating Antagonism between Transcription and Proliferation Allows Near-Deterministic Cellular Reprogramming. Cell Stem Cell, 2019, 25, 486-500.e9.	5.2	34

#	Article	IF	Citations
55	Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. International Journal of Stroke, 2019, , 174749301987191.	2.9	13
56	Pericyte constriction underlies capillary derecruitment during hyperemia in the setting of arterial stenosis. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H255-H263.	1.5	18
57	Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nature Neuroscience, 2019, 22, 1089-1098.	7.1	246
58	Short-term fish oil supplementation applied in presymptomatic stage of Alzheimer's disease enhances microglial/macrophage barrier and prevents neuritic dystrophy in parietal cortex of 5xFAD mouse model. PLoS ONE, 2019, 14, e0216726.	1.1	16
59	TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice. Cell Reports, 2019, 27, 549-560.e6.	2.9	43
60	O3â€01â€01: INTERACTION BETWEEN OBESITY, BRAIN HDL, AND APOE4 GENOTYPE IN CEREBRAL AMYLOIDOSIS. Alzheimer's and Dementia, 2019, 15, P875.	0.4	0
61	Undetectable gadolinium brain retention in individuals with an ageâ€dependent bloodâ€brain barrier breakdown in the hippocampus and mild cognitive impairment. Alzheimer's and Dementia, 2019, 15, 1568-1575.	0.4	22
62	P4â€527: PERICYTE CONTRACTILITY BY OPTOGENETICS REGULATES CAPILLARY DIAMETER AND BLOOD FLOW. Alzheimer's and Dementia, 2019, 15, P1516.	0.4	0
63	Final Results of the RHAPSODY Trial: A Multiâ€Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Annals of Neurology, 2019, 85, 125-136.	2.8	113
64	Prion Protein Antagonists Rescue Alzheimerâ€™s Amyloid-Î²-Related Cognitive Deficits. Trends in Molecular Medicine, 2019, 25, 74-76.	3.5	5
65	Vascular dysfunctionâ€”The disregarded partner of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 158-167.	0.4	454
66	Bloodâ€“brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine, 2019, 25, 270-276.	15.2	987
67	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. Journal of Experimental Medicine, 2019, 216, 279-293.	4.2	55
68	Blood-Brain Barrier: From Physiology to Disease and Back. Physiological Reviews, 2019, 99, 21-78.	13.1	1,232
69	Experimental chronic cerebral hypoperfusion results in decreased pericyte coverage and increased bloodâ€“brain barrier permeability in the corpus callosum. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 240-250.	2.4	60
70	Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight, 2019, 4, .	2.3	37
71	Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. Neurosurgery, 2018, 82, 770-780.	0.6	35
72	Permeability imaging as a predictor of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 973-979.	2.4	24

#	ARTICLE	IF	CITATIONS
73	Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nature Medicine, 2018, 24, 313-325.	15.2	445
74	Bloodâ€“brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology, 2018, 14, 133-150.	4.9	1,731
75	PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood, 2018, 131, 1163-1171.	0.6	81
76	Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovascular Research, 2018, 114, 1462-1473.	1.8	211
77	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. Neuropharmacology, 2018, 134, 293-301.	2.0	15
78	2313 Characterization of the host pericyte role in glioblastoma angiogenesis. Journal of Clinical and Translational Science, 2018, 2, 1-1.	0.3	0
79	F1â€03â€04: ALZHEIMER'S DISEASE: A MATTER OF BLOODâ€BRAIN BARRIER DYSFUNCTION?. Alzheimer's and Dementia, 2018, 14, P205.	0.4	0
80	The role of brain vasculature in neurodegenerative disorders. Nature Neuroscience, 2018, 21, 1318-1331.	7.1	612
81	Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-Î²42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration, 2018, 13, 57.	4.4	164
82	In vivo imaging and analysis of cerebrovascular hemodynamic responses and tissue oxygenation in the mouse brain. Nature Protocols, 2018, 13, 1377-1402.	5.5	45
83	A lymphatic waste-disposal system implicated in Alzheimerâ€™s disease. Nature, 2018, 560, 172-174.	13.7	23
84	Activated protein C, protease activated receptor 1, and neuroprotection. Blood, 2018, 132, 159-169.	0.6	94
85	Altered Permeability Of The Blood-CSF Barrier In Chronic Migraine. FASEB Journal, 2018, 32, 922.6-922.6.	0.2	0
86	Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nature Neuroscience, 2017, 20, 406-416.	7.1	383
87	Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nature Reviews Neuroscience, 2017, 18, 419-434.	4.9	842
88	Remote control of BBB: A tale of exosomes and microRNA. Cell Research, 2017, 27, 849-850.	5.7	54
89	Alzheimerâ€™s disease: A matter of bloodâ€“brain barrier dysfunction?. Journal of Experimental Medicine, 2017, 214, 3151-3169.	4.2	467
90	Role of clusterin in the brain vascular clearance of amyloid-Î². Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8681-8682.	3.3	79

#	ARTICLE	IF	CITATIONS
91	NIH workshop report on the trans-agency bloodâ€“brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface. Fluids and Barriers of the CNS, 2017, 14, 12.	2.4	16
92	Regional early and progressive loss of brain pericytes but not vascular smooth muscle cells in adult mice with disrupted platelet-derived growth factor receptor-Î² signaling. PLoS ONE, 2017, 12, e0176225.	1.1	85
93	Neurovascular and Immuno-Imaging: From Mechanisms to Therapies. Proceedings of the Inaugural Symposium. Frontiers in Neuroscience, 2016, 10, 46.	1.4	3
94	FTS3â€02â€03: Interactions of Vascular and Alzheimer Disease. Alzheimer's and Dementia, 2016, 12, P278.	0.4	0
95	Pericytes of the neurovascular unit: key functions and signaling pathways. Nature Neuroscience, 2016, 19, 771-783.	7.1	766
96	Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. Thrombosis Research, 2016, 141, S62-S64.	0.8	33
97	Brain imaging of neurovascular dysfunction in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 131, 687-707.	3.9	160
98	Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy. Cell Stem Cell, 2016, 19, 663-671.	5.2	437
99	3K3Aâ€“activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. Nature Medicine, 2016, 22, 1050-1055.	15.2	88
100	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2143-2151.	1.1	32
101	Optimal acquisition and modeling parameters for accurate assessment of low K_{trans} blood-brain barrier permeability using dynamic contrast-enhanced MRI. Magnetic Resonance in Medicine, 2016, 75, 1967-1977.	1.9	87
102	Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 887-900.	1.8	405
103	Blood-Brain Barrier Permeability and Gadolinium. JAMA Neurology, 2016, 73, 13.	4.5	77
104	Consensus statement for diagnosis of subcortical small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 6-25.	2.4	173
105	Accelerated pericyte degeneration and bloodâ€“brain barrier breakdown in apolipoprotein E4 carriers with Alzheimerâ€™s disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 216-227.	2.4	464
106	Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke. Blood, 2016, 128, 13-13.	0.6	1
107	Activated protein C: biased for translation. Blood, 2015, 125, 2898-2907.	0.6	212
108	Impaired vascular-mediated clearance of brain amyloid beta in Alzheimerâ€™s disease: the role, regulation and restoration of LRP1. Frontiers in Aging Neuroscience, 2015, 7, 136.	1.7	160

#	ARTICLE	IF	CITATIONS
109	Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. Frontiers in Cellular Neuroscience, 2015, 9, 344.	1.8	20
110	Central role for PICALM in amyloid-Î² blood-brain barrier transcytosis and clearance. Nature Neuroscience, 2015, 18, 978-987.	7.1	334
111	ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Medical Imaging, 2015, 15, 19.	1.4	63
112	7T multi-shell hybrid diffusion imaging (HYDI) for mapping brain connectivity in mice. Proceedings of SPIE, 2015, 9413, .	0.8	9
113	S1-01-02: Blood-brain barrier mechanisms of neurodegeneration in Alzheimer's disease. , 2015, 11, P114-P114.		1
114	Blood-Brain Barrier Breakdown in the Aging Human Hippocampus. Neuron, 2015, 85, 296-302.	3.8	1,436
115	GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nature Neuroscience, 2015, 18, 521-530.	7.1	496
116	Clearance systems in the brainâ€"implications for Alzheimer disease. Nature Reviews Neurology, 2015, 11, 457-470.	4.9	1,127
117	Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1055-1068.	2.4	92
118	Vascular Plasticity and Cognition During Normal Aging and Dementia. JAMA Neurology, 2015, 72, 495.	4.5	30
119	Shedding of soluble platelet-derived growth factor receptor-Î² from human brain pericytes. Neuroscience Letters, 2015, 607, 97-101.	1.0	97
120	Establishment and Dysfunction of the Blood-Brain Barrier. Cell, 2015, 163, 1064-1078.	13.5	1,146
121	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 710-717.	0.4	461
122	Bloodâ€"spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1035-42.	3.3	188
123	Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thrombosis and Haemostasis, 2014, 112, 883-892.	1.8	43
124	Recommendations of the Alzheimer's Diseaseâ€"Related Dementias Conference. Neurology, 2014, 83, 851-860.	1.5	103
125	Negative regulation of NF-ÎºB activity by brain-specific TRIpartite Motif protein 9. Nature Communications, 2014, 5, 4820.	5.8	62
126	The Pericyte: A Forgotten Cell Type with Important Implications for <scp>A</scp>lzheimer's Disease?. Brain Pathology, 2014, 24, 371-386.	2.1	198

#	ARTICLE	IF	CITATIONS
127	Blood-Brain Barrier: A Dual Life of MFSD2A?. Neuron, 2014, 82, 728-730.	3.8	45
128	P2-120: INCREASED CSF MATRIX METALLOPROTEINASE-9 (MMP-9) AND REDUCED WHITE MATTER INTEGRITY IN HEALTHY ELDERLY. , 2014, 10, P515-P515.		0
129	Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. Current Pharmaceutical Design, 2014, 19, 7479-7485.	0.9	61
130	Bloodâ€“spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathologica, 2013, 125, 111-120.	3.9	263
131	Cerebrovascular Effects of Apolipoprotein E. JAMA Neurology, 2013, 70, 440.	4.5	218
132	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Research, 2013, 1507, 97-104.	1.1	25
133	Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells, Molecules, and Diseases, 2013, 51, 104-108.	0.6	9
134	An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR₁-Akt Pathway. Journal of Neuroscience, 2013, 33, 6181-6190.	1.7	54
135	Relationship Between Cyclophilin A Levels and Matrix Metalloproteinase 9 Activity in Cerebrospinal Fluid of Cognitively Normal Apolipoprotein E4 Carriers and Blood-Brain Barrier Breakdown. JAMA Neurology, 2013, 70, 1198.	4.5	93
136	Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. Stroke, 2013, 44, 3529-3536.	1.0	56
137	A gliovascular idea for the white matter repair?. Journal of Neurochemistry, 2013, 125, 172-174.	2.1	2
138	A Lipoprotein Receptor Cluster IV Mutant Preferentially Binds Amyloid-Î² and Regulates Its Clearance from the Mouse Brain. Journal of Biological Chemistry, 2013, 288, 15154-15166.	1.6	33
139	Deficiency in Mural Vascular Cells Coincides with Bloodâ€“Brain Barrier Disruption in <scp>A</scp>lzheimer's Disease. Brain Pathology, 2013, 23, 303-310.	2.1	409
140	Bloodâ€“Spinal Cord Barrier Pericyte Reductions Contribute to Increased Capillary Permeability. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1841-1852.	2.4	171
141	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood AÎ² clearance in a mouse model of Î²-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15502-15507.	3.3	138
142	Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke. Current Pharmaceutical Design, 2012, 18, 4215-4222.	0.9	50
143	Neurovascular Defects and Faulty Amyloid-Î² Vascular Clearance in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S87-S100.	1.2	100
144	An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents. Stroke, 2012, 43, 2444-2449.	1.0	65

#	ARTICLE	IF	CITATIONS
145	Neurovascular Dysfunction and Faulty Amyloid Â-Peptide Clearance in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011452-a011452.	2.9	207
146	Protein C anticoagulant and cytoprotective pathways. International Journal of Hematology, 2012, 95, 333-345.	0.7	110
147	Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature, 2012, 485, 512-516.	13.7	1,019
148	A multimodal RAGE-specific inhibitor reduces amyloid Î²â€“mediated brain disorder in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 2012, 122, 1377-1392.	3.9	507
149	Hypertension Induces Brain Î²-Amyloid Accumulation, Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for Advanced Glycation End Products in Brain Vasculature. Hypertension, 2012, 60, 188-197.	1.3	199
150	Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews Neuroscience, 2011, 12, 723-738.	4.9	2,254
151	Lack of Smad or Notch Leads to a Fatal Game of Brain Pericyte Hopscotch. Developmental Cell, 2011, 20, 279-280.	3.1	24
152	Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends in Neurosciences, 2011, 34, 198-209.	4.2	129
153	Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-Î² is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 25-34.	1.2	63
154	Methamphetamine causes sustained depression in cerebral blood flow. Brain Research, 2011, 1373, 91-100.	1.1	50
155	Central nervous system pericytes in health and disease. Nature Neuroscience, 2011, 14, 1398-1405.	7.1	806
156	From the liver to the bloodâ€“brain barrier: An interconnected system regulating brain amyloidâ€Î² levels. Journal of Neuroscience Research, 2011, 89, 967-968.	1.3	24
157	Microhemorrhages: Undetectable but clinically meaningful the question persists. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 231-232.	2.3	2
158	Activated Protein C is Neuroprotective and Mediates New Blood Vessel Formation and Neurogenesis After Controlled Cortical Impact. Neurosurgery, 2010, 66, 165-172.	0.6	55
159	Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood, 2010, 115, 4963-4972.	0.6	95
160	Impaired spine formation and learning in GPCR kinase 2 interacting protein-1 (GIT1) knockout mice. Brain Research, 2010, 1317, 218-226.	1.1	42
161	Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Research, 2010, 1347, 125-131.	1.1	36
162	Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Molecular Neurodegeneration, 2010, 5, 32.	4.4	274

#	Article	IF	Citations
163	Lowâ€density lipoprotein receptorâ€related proteinâ€1: a serial clearance homeostatic mechanism controlling Alzheimerâ€™s amyloid Î²â€peptide elimination from the brain. Journal of Neurochemistry, 2010, 115, 1077-1089.	2.1	212
164	Neurodegeneration and the neurovascular unit. Nature Medicine, 2010, 16, 1370-1371.	15.2	174
165	Protein S Protects Neurons from Excitotoxic Injury by Activating the TAM Receptor Tyro3â€“Phosphatidylinositol 3-Kinaseâ€“Akt Pathway through Its Sex Hormone-Binding Globulin-Like Region. Journal of Neuroscience, 2010, 30, 15521-15534.	1.7	57
166	Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging. Neuron, 2010, 68, 409-427.	3.8	1,192
167	Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica, 2009, 94, 1721-1731.	1.7	19
168	Neurovascular mechanisms and bloodâ€“brain barrier disorder in Alzheimerâ€™s disease. Acta Neuropathologica, 2009, 118, 103-113.	3.9	769
169	Endothelial Protein C Receptor-Assisted Transport of Activated Protein C across the Mouse Bloodâ€”Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 25-33.	2.4	64
170	SRF and myocardin regulate LRP-mediated amyloid-Î² clearance in brain vascular cells. Nature Cell Biology, 2009, 11, 143-153.	4.6	237
171	Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. European Journal of Neuroscience, 2009, 29, 1119-1130.	1.2	83
172	Speciesâ€dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. Journal of Neurochemistry, 2009, 109, 116-124.	2.1	33
173	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. Journal of Clinical Investigation, 2009, 119, 3437-49.	3.9	158
174	Differential Neuroprotection and Risk for Bleeding From Activated Protein C With Varying Degrees of Anticoagulant Activity. Stroke, 2009, 40, 1864-1869.	1.0	52
175	New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease. Neurotherapeutics, 2008, 5, 409-414.	2.1	138
176	ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nature Neuroscience, 2008, 11, 420-422.	7.1	409
177	Coupling of Angiogenesis and Neurogenesis in Cultured Endothelial Cells and Neural Progenitor Cells after Stroke. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 764-771.	2.4	230
178	The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron, 2008, 57, 178-201.	3.8	2,712
179	Myocardin Is Sufficient for a Smooth Muscle-Like Contractile Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1505-1510.	1.1	112
180	apoE isoformâ€“specific disruption of amyloid Î² peptide clearance from mouse brain. Journal of Clinical Investigation, 2008, 118, 4002-4013.	3.9	623

#	ARTICLE	IF	CITATIONS
181	Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1. Journal of Neuroscience, 2008, 28, 12788-12797.	1.7	104
182	Endothelial Cell Protein C Receptor. Circulation Research, 2007, 100, 155-157.	2.0	601
183	Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease. Current Alzheimer Research, 2007, 4, 191-197.	0.7	333
184	Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 823-828.	3.3	189
185	The cytoprotective protein C pathway. Blood, 2007, 109, 3161-3172.	0.6	714
186	Clearance of amyloid-Î² by circulating lipoprotein receptors. Nature Medicine, 2007, 13, 1029-1031.	15.2	381
187	Transport Pathways for Clearance of Human Alzheimer's Amyloid Î²-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 909-918.	2.4	576
188	Two-Photon Imaging of Astrocytic Ca2+ Signaling and the Microvasculature in Experimental Mice Models of Alzheimer's Disease. Annals of the New York Academy of Sciences, 2007, 1097, 40-50.	1.8	145
189	The promise of protein C. Blood Cells, Molecules, and Diseases, 2006, 36, 211-216.	0.6	45
190	Remodeling after stroke. Nature Medicine, 2006, 12, 390-391.	15.2	59
191	Activated protein C inhibits tissue plasminogen activatorâ€“induced brain hemorrhage. Nature Medicine, 2006, 12, 1278-1285.	15.2	243
192	Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nature Medicine, 2005, 11, 959-965.	15.2	274
193	Functional recovery after embolic stroke in rodents by activated protein C. Annals of Neurology, 2005, 58, 474-477.	2.8	67
194	IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid Â Peptide by the Blood-Brain Barrier Neonatal Fc Receptor. Journal of Neuroscience, 2005, 25, 11495-11503.	1.7	238
195	Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends in Neurosciences, 2005, 28, 202-208.	4.2	856
196	Neurovascular Pathways and Alzheimer Amyloid Î²-peptide. Brain Pathology, 2005, 15, 78-83.	2.1	95
197	P-glycoprotein deficiency at the blood-brain barrier increases amyloid-Â deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation, 2005, 115, 3285-3290.	3.9	564
198	RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid Â-Peptide Clearance Through Transport Across the Blood-Brain Barrier. Stroke, 2004, 35, 2628-2631.	1.0	362

#	ARTICLE	IF	CITATIONS
199	Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid Î²-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid Î²-Protein Precursor. Journal of Biological Chemistry, 2004, 279, 20296-20306.	1.6	315
200	Clearing amyloid through the blood-brain barrier. Journal of Neurochemistry, 2004, 89, 807-811.	2.1	324
201	Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nature Medicine, 2004, 10, 1379-1383.	15.2	205
202	Advances in restorative neurosurgery: Endovascular delivery and fate determination of transplanted stem cells. Seminars in Anesthesia, 2004, 23, 248-257.	0.3	0
203	Method for measurement of the bloodâ€“brain barrier permeability in the perfused mouse brain: application to amyloid-Î² peptide in wild type and Alzheimerâ€™s Tg2576 mice. Journal of Neuroscience Methods, 2004, 138, 233-242.	1.3	57
204	Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrinâ€bound and free iron into the rat brain. Journal of Neurochemistry, 2004, 88, 813-820.	2.1	94
205	LRP/Amyloid Î²-Peptide Interaction Mediates Differential Brain Efflux of Aî² Isoforms. Neuron, 2004, 43, 333-344.	3.8	752
206	Presence and Functional Activity of the Aryl Hydrocarbon Receptor in Isolated Murine Cerebral Vascular Endothelial Cells and Astrocytes. NeuroToxicology, 2004, 25, 605-616.	1.4	68
207	Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. Neuron, 2004, 41, 563-572.	3.8	243
208	Activated protein C and ischemic stroke. Critical Care Medicine, 2004, 32, S247-S253.	0.4	47
209	A simple method for isolation and characterization of mouse brain microvascular endothelial cells. Journal of Neuroscience Methods, 2003, 130, 53-63.	1.3	106
210	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Medicine, 2003, 9, 338-342.	15.2	556
211	RAGE mediates amyloid-Î² peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine, 2003, 9, 907-913.	15.2	1,277
212	Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells, Molecules, and Diseases, 2003, 30, 271-276.	0.6	71
213	Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice. Circulation, 2003, 107, 1791-1796.	1.6	86
214	Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood, 2003, 101, 4797-4801.	0.6	107
215	Endovascular Restorative Neurosurgery: A Novel Concept for Molecular and Cellular Therapy of the Nervous System. Neurosurgery, 2003, 52, 402-413.	0.6	27
216	Brain Clearance of Alzheimer's Amyloid-Î²40 in the Squirrel Monkey: A SPECT Study in a Primate Model of Cerebral Amyloid Angiopathy. Journal of Drug Targeting, 2002, 10, 359-368.	2.1	89

#	ARTICLE	IF	CITATIONS
217	Activated protein C: Potential therapy for severe sepsis, thrombosis, and stroke. Seminars in Hematology, 2002, 39, 197-205.	1.8	85
218	Vascular disorder in Alzheimerâ€™s disease: role in pathogenesis of dementia and therapeutic targets. Advanced Drug Delivery Reviews, 2002, 54, 1553-1559.	6.6	56
219	Circulating amyloid-Î² peptide crosses the bloodâ€“brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascular Pharmacology, 2002, 38, 303-313.	1.0	127
220	Current treatments and therapeutic targets in Alzheimer's disease. Advanced Drug Delivery Reviews, 2002, 54, 1533-7.	6.6	2
221	Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an Î±v Integrin Antagonist. Neurosurgery, 2001, 48, 151-157.	0.6	157
222	Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke. Circulation, 2001, 103, 1799-1805.	1.6	202
223	Apolipoprotein J (clusterin) and Alzheimer's disease. Microscopy Research and Technique, 2000, 50, 305-315.	1.2	226
224	Brain Injury and Cerebrovascular Fibrin Deposition Correlate with Reduced Antithrombotic Brain Capillary Functions in a Hypertensive Stroke Model. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 998-1009.	2.4	20
225	Differential Regulation of Leptin Transport by the Choroid Plexus and Blood-Brain Barrier and High Affinity Transport Systems for Entry into Hypothalamus and Across the Blood-Cerebrospinal Fluid Barrier*. Endocrinology, 2000, 141, 1434-1441.	1.4	147
226	Clearance of Alzheimerâ€™s amyloid-Î²1-40 peptide from brain by LDL receptorâ€“related protein-1 at the blood-brain barrier. Journal of Clinical Investigation, 2000, 106, 1489-1499.	3.9	1,213
227	Apolipoprotein J (clusterin) and Alzheimer's disease. , 2000, 50, 305.		5
228	Retroviral Vector-Mediated Transfer and Expression of Human Tissue Plasminogen Activator cDNA in Bovine Brain Endothelial Cells. Neurosurgery, 1999, 45, 962-970.	0.6	7
229	Tissue Plasminogen Activator (tPA) Deficiency Exacerbates Cerebrovascular Fibrin Deposition and Brain Injury in a Murine Stroke Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2801-2806.	1.1	127
230	Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharmaceutical Research, 1999, 16, 1360-1365.	1.7	34
231	Exogenous microglia enter the brain and migrate into ischaemic hippocampal lesions. Neuroscience Letters, 1999, 272, 127-130.	1.0	25
232	Corneal Transport of Circulating Glutathione in Normal and Galactosemic Guinea Pigs. Cornea, 1999, 18, 321.	0.9	16
233	Measurement of Thrombomodulin mRNA Expression in Brain Capillaries by Polymerase Chain Reaction. Thrombosis Research, 1998, 91, 191-197.	0.8	7
234	Rat Brain Capillary Thrombomodulin. Thrombosis Research, 1998, 92, 213-219.	0.8	6

#	ARTICLE	IF	CITATIONS
235	Circulating Antibody against Tumor Necrosis Factorâ€“Alpha Protects Rat Brain from Reperfusion Injury. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 52-58.	2.4	179
236	Immunohistochemical Localization of Tissue Plasminogen Activator in Vascular Endothelium of Stroke-prone Regions of the Rat Brain. Neurosurgery, 1998, 43, 909-913.	0.6	27
237	Strategies to Circumvent Vascular Barriers of the Central Nervous System. Neurosurgery, 1998, 43, 877-878.	0.6	46
238	Survival and Toxicity of an Allogeneic Cytokine-secreting Fibroblast Vaccine in the Central Nervous System. Neurosurgery, 1998, 42, 340-340.	0.6	0
239	Cerebrovascular Accumulation and Increased Bloodâ€Brain Barrier Permeability to Circulating Alzheimer's Amyloid Î² Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. Journal of Neurochemistry, 1998, 70, 210-215.	2.1	128
240	Detection of Brain Tumor Invasion and Micrometastasis in Vivo by Expression of Enhanced Green Fluorescent Protein. Neurosurgery, 1998, 43, 1437-1442.	0.6	27
241	Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part I: Target Disorders and Concept Approaches to Gene Therapy of the Central Nervous System. Neurosurgery, 1997, 40, 789-804.	0.6	97
242	Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part II: Vector Systems and Delivery Methodologies for Gene Therapy of the Central Nervous System. Neurosurgery, 1997, 40, 805-813.	0.6	117
243	Neuroprotective effects of nicardipine in a rat model of ischemia and reperfusion. Neurosurgical Focus, 1997, 2, E4.	1.0	1
244	Attenuation of brain injury and reduction of neuron-specific enolase by nicardipine in systemic circulation following focal ischemia and reperfusion in a rat model. Journal of Neurosurgery, 1997, 87, 731-737.	0.9	31
245	Liver and lens glutathione and cysteine regulation in galactose-fed guinea pigs. Current Eye Research, 1997, 16, 365-371.	0.7	6
246	Low de novo Glutathione Synthesis from Circulating Sulfur Amino Acids in the Lens Epithelium. Experimental Eye Research, 1997, 64, 615-626.	1.2	10
247	Thrombomodulin Expression in Bovine Brain Capillaries. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3139-3146.	1.1	36
248	Chronic Nicotine Treatment Enhances Focal Ischemic Brain Injury and Depletes Free Pool of Brain Microvascular Tissue Plasminogen Activator in Rats. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 136-146.	2.4	109
249	Intravenous infusion of RMP-7 increases ocular uptake of ganciclovir. Pharmaceutical Research, 1997, 14, 80-85.	1.7	9
250	Isoformâ€Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Bloodâ€Brain Barrier Transport of Circulating Alzheimer's Amyloid Î². Journal of Neurochemistry, 1997, 69, 1995-2004.	2.1	138
251	Cerebrovascular transport of Alzheimer's amyloidÎ² and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier. Life Sciences, 1996, 59, 1483-1497.	2.0	135
252	Transport of Circulating Reduced Glutathione at the Basolateral Side of the Anterior Lens Epithelium: Physiologic Importance and Manipulations. Experimental Eye Research, 1996, 62, 29-38.	1.2	44

#	Article	IF	Citations
253	Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid Î² in guinea pigs. Neuroscience Letters, 1996, 206, 157-160.	1.0	84
254	Cellular Uptake and Transport of Methylprednisolone at the Blood-Brain Barrier. Neurosurgery, 1996, 38, 348-354.	0.6	24
255	Transport of dopamine at the blood-brain barrier of the guinea pig: inhibition by psychotropic drugs and nicotine. Pharmaceutical Research, 1996, 13, 290-295.	1.7	14
256	Evidence for the Existence of a Sodium-dependent Glutathione (GSH) Transporter. Journal of Biological Chemistry, 1996, 271, 9754-9758.	1.6	67
257	Brain Capillary Tissue Plasminogen Activator in a Diabetes Stroke Model. Stroke, 1996, 27, 712-719.	1.0	41
258	Expression of Tissue Plasminogen Activator in Cerebral Capillaries. Neurosurgery, 1995, 37, 955-960.	0.6	58
259	Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharmaceutical Research, 1995, 12, 1395-1406.	1.7	124
260	Blood-to-lens Transport of Reduced Glutathione in an In Situ Perfused Guinea-pig Eye. Experimental Eye Research, 1994, 59, 487-496.	1.2	19
261	A Simple Technique to Determine Glutathione (GSH) Levels and Synthesis in Ocular Tissues as GSH-bimane Adduct: Application to Normal and Galactosemic Guinea-pigs. Experimental Eye Research, 1993, 56, 45-50.	1.2	29
262	Transport, uptake, and metabolism of blood-borne vasopressin by the blood-brain barrier. Brain Research, 1992, 590, 213-218.	1.1	45
263	An in situ perfused guinea-pig eye model for blood-ocular transport studies: Application to amino acids. Experimental Eye Research, 1992, 54, 471-477.	1.2	12
264	In vivo approaches for studying peptide interactions at the blood â€" brain barrier. Journal of Controlled Release, 1990, 13, 185-201.	4.8	21
265	Kinetic Analysis of Leucine-Enkephalin Cellular Uptake at the Luminal Side of the Blood-Brain Barrier of an In Situ Perfused Guinea-Pig Brain. Journal of Neurochemistry, 1989, 53, 1333-1340.	2.1	85
266	Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. Peptides, 1989, 10, 249-254.	1.2	32
267	Chronic amphetamine intoxication and the blood-brain barrier permeability to inert polar molecules studied in the vascularly perfused guinea pig brain. Journal of the Neurological Sciences, 1989, 94, 41-50.	0.3	15
268	Unidirectional uptake of enkephalins at the blood-tissue interface of the blood-cerebrospinal fluid barrier: a saturable mechanism. Regulatory Peptides, 1988, 20, 33-44.	1.9	27
269	Passage of delta sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier. Peptides, 1988, 9, 533-538.	1.2	28
270	Transport of Leucine-Enkephalin Across the Blood-Brain Barrier in the Perfused Guinea Pig Brain. Journal of Neurochemistry, 1987, 49, 310-315.	2.1	120

#	Article	IF	Citations
271	Blood-brain barrier permeability to leucine-enkephalin,d-Alanine2-d-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Research, 1985, 336, 125-132.	1.1	111
272	Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Research, 1985, 358, 191-199.	1.1	93
273	Blood-brain barrier permeability to dipeptides and their constituent amino acids. Brain Research, 1983, 271, 65-71.	1.1	36
274	PROTECTIVE EFFECTS OF GLUCAGON DURING THE ANAPHYLACTIC RESPONSE IN GUINEAâ€PIG ISOLATED HEART. British Journal of Pharmacology, 1982, 76, 483-489.	2.7	8